The 9th Annual Pain & Migraine Therapeutics Summit

October 20, 2015

Washington, DC    September 23-24, 2015


This is a two-day conference with presentations of the latest research and pharmaceutical findings regarding pain management and migraine disease.

Participants: 80 and include representatives from CRO’s (Clinical Research Organizations), pharmaceutical companies and basic researchers – no clinicians

Range of topics

  • New animal and human study models

  • New clinical measurements of pain

  • New directions in pathophysiology

  • Reports on the development of new medications

Trends

  • New refinements in the understanding how migraine disease happens

  • New medications are going to be larger molecules and therefore can be more chemically manipulated to allow more specific targets, but this means that they will be delivered by intravenous or subcutaneous methods, not orally.

  • Continued NIH funding concerns

Most interesting reports

  • New medications will be entering the market or show promise in early stages of testing.

  1. TEV 48125 – a monthly subcutaneous CGRP antibody
    There are three other CGRP antibodies that are variations of this molecule – each resolving the initial problem with liver toxicity and there is a difference in their target strategy.  No information yet about pricing or differences in efficacy.

  2. topical nonsteroidal anti-inflammatory agent, Topofen (Achelios Therapeutics)
    indicated for people with 2-4 migraines a month – apply to the temples and around the ears – 80% absorbed and deposited into the fat.  Prolongs half-life to 8 hours – minimal plasma levels – onset of pain relief 30 min, lasts 24 hours
    50% report pain free (placebo 27%), 67% report reduction in pain intensity with fewer related symptoms (light sensitivity and nausea)

  3. propofol nasal spray

  • Treximet (Pernix Therapeutics) now has an indicated use in children 12 years and older for acute migraine with and without aura (5-21-15)

  • Tramadol now has an FDA warning that it is difficult to metabolize in patients of age 12-18

Strengths

  • Small (80) participants allows a great opportunity for networking

  • Understanding the challenges of developing new treatments

Weaknesses

  • Some information about other forms of pain control (narcotics and neuropathic pain) are not very relevant to migraine disorders